This page contains a Flash digital edition of a book.
Life Sciences Intellectual Property Review is published by: Newton Media Limited 15-17 Newton Way

Woolsthorpe-by-Colsterworth NG33 5NR United Kingdom Telephone: +44 203 301 8200

Directors and publishers Nicholas Lipinski and John Eddington Editor

Peter Scott

Telephone: +44 203 301 8211 Email:

Sub-editor Susan Gault

Journalist Mark Dugdale

Associate publisher John Haley

Telephone: +44 203 301 8205 Email:

Advertising manager Matt Saunders

Telephone: +44 1926 423 781 Email:

Production and design

Strano & Pettigrew Design Associates

©Newton Media Limited 2011

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electrical, mechanical, photocopying,

recording or otherwise without the prior written permission of the publisher.

The views expressed in Life Sciences Intellectual Property Review are not necessarily those shared by the publisher, Newton Media Limited. Wishing to reflect the true nature of the market, we have included articles from a number of sources, and the views expressed are those of the individual contributors. No responsibility or liability is accepted by Newton Media Limited for any loss to any person, legal or physical, as a result of any statement, fact or figure contained in Life Sciences Intellectual Property Review.

This publication is not a substitute for advice on a specific transaction.

The publication of advertisements does not represent endorsement by the publisher.

Life Sciences Intellectual Property Review: ISSN 1758-7528 (Print) Cover image:

© /JanPietruszka

Te life sciences and biotech industry has a bright future. Indeed, it is likely to provide a large proportion of innovative medical solutions in this century. IP remains absolutely central to the success of that project. While it will certainly come under greater pressure from those who believe that companies should be obliged to share potentially life-saving innovations, and from those who see ethical and moral peril in the very notion of biotechnological research, IP, some international divergence in practice notwithstanding, has proven itself to be the best system we have. Why change a winning formula?

Peter Scott Editor


Stefan Abel, partner, Bardehle Pagenberg

Roberto Arochi, partner, Arochi Marroquín & Lindner SC

Roberto Barchiesi, president, International AntiCounterfeiting Coalition

Colin Davies, director, intellectual property law unit, University of Glamorgan

Michael Factor, partner, JMB Fa©tor & Co

Ronald Faggetter, managing partner, Smart & Biggar/ Fetherstonhaugh

Maurice Gonsalves, partner, Mallesons Stephen Jacques

Richard Gough partner, Baker & McKenzie

Chris McLeod, director of trademarks, Squire Sanders Hammonds

Jacqueline Needle, partner, Beck Greener

Sergio Olivares, partner, Olivares & Cia

John Pegram, senior principal, Fish and Richardson PC

Rebecca L. Roby, senior director of business affairs, Hard Rock International

Pier Luigi Roncaglia, partner, Studio Legale SIB

Mario Soerensen Garcia, founder and managing partner, Soerensen Garcia Advogados Associados

Paul J. Sutton, co-founding partner, Sutton Magidoff LLP

Stephen Yang, partner, Peksung Intellectual Property

EDITOR’S NOTE On the verge

In the biotech and life sciences industry, very little is clear-cut. Innovation ensures that the industry continues to grow, but also brings uncertainty, commercial and ethical, as companies push the boundaries of the possible. While it is not mainstream yet, there is a noisy body of opposition to many of the industry’s most exciting discoveries, while courts across the world are only slowly delivering decisions that will provide the necessary legal certainly to innovators.

And in the US, which remains the world’s leading innovator jurisdiction in biotech and life sciences, companies face a lack of clarity at every turn. Te implications of 2010’s healthcare reform are yet to be fully understood; whether there will be patent reform, and if so, how it will look, is another unknown. Add to this the looming spectre of the Myriad gene patent case, which is currently on appeal but could have disastrous implications for a host of innovative companies, and it is clear that the industry has much to ponder.

But it’s not all doom and gloom. As Jim Greenwood, president of the Biotechnology Industry Organization, tells us in an interview, investment is returning to the sector, though not yet at pre-recession levels. And in some of the non-traditional life sciences jurisdictions, business is good and growing.

We hear from India, where some have talked of a biotech ‘revolution’, and consider the leading life sciences jurisdictions in Europe. We look at the potential damage of counterfeit drugs and how best to tackle that menace—with manufacturers from Asia, imports to many countries across the world, and a burgeoning Internet trade (estimates suggest that 50 percent of drugs available on the Internet are fake) combining to leave brand owners facing threats from all sides. We look at some of the options for brand owners to effectively partner with law enforcement and other institutions to look aſter their assets.

Life Sciences Intellectual Property Review 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84